论文部分内容阅读
目的:观察中药癌理通外敷联合奥施康定口服治疗中、重度肝区癌痛的临床疗效。方法:采用分组随机化、双盲、平行、对照临床试验方案,将78例患者分为治疗组和对照组各39例。治疗组予癌理通外敷联合奥施康定治疗,对照组予安慰剂外敷联合奥施康定治疗。比较2组镇痛疗效、所需奥施康定用量及不良反应发生情况。结果:平均镇痛起效时间治疗组为45.7min,对照组为47.3min。2组比较,差异无显著性意义(P>0.05)。但镇痛维持时间治疗组为(13.65±1.73)h,对照组为(11.37±2.04)h,2组比较,差异有非常显著性意义(P<0.01)。2组各程度疼痛缓解率比较,差异无显著性意义(P>0.05)。治疗组所需奥施康定用量较对照组明显减少,2组比较,差异有非常显著性意义(P<0.01)。2组不良反应发生率比较,差异无显著性意义(P>0.05)。结论:癌理通外敷治疗中、重度肝区癌痛可以增加奥施康定镇痛的维持时间,减少奥施康定的使用剂量,对镇痛早期难以耐受奥施康定恶心呕吐不良反应,具有增效减毒作用。
Objective: To observe the clinical efficacy of traditional Chinese medicine combined with cancer through the orally with OxyContin in the treatment of moderate and severe liver cancer pain. Methods: Randomized, double-blind, parallel and controlled clinical trial of 78 patients were divided into treatment group and control group of 39 cases. The patients in the treatment group received Oxycodin treatment combined with cancer therapy and the control group received placebo topical and OxyContin treatment. The analgesic effects of the two groups were compared, and the dosage of oxycodin required and the occurrence of adverse reactions were compared. Results: The mean time to onset of analgesia was 45.7 minutes in the treatment group and 47.3 minutes in the control group. There was no significant difference between the two groups (P> 0.05). However, the duration of analgesia was (13.65 ± 1.73) h in the treatment group and (11.37 ± 2.04) h in the control group, with significant difference between the two groups (P <0.01). There was no significant difference between the two groups in pain relief (P> 0.05). The amount of oxycodin required in the treatment group was significantly reduced compared with the control group, the difference was statistically significant (P <0.01). There was no significant difference between the two groups in the incidence of adverse reactions (P> 0.05). Conclusions: The treatment of cancer through the external application, severe liver cancer pain can increase the duration of the oxycodone analgesia, reduce the dose of oxycodone on the early pain of refractory to Oxadimene nausea and vomiting adverse reactions, with increased Effective attenuated effect.